Home / Available CME / Therapy for Life - Live Programs
Back to Top
Credit Designation Statement
Back to Top
Therapy for Life: Improving the Treatment of Antiretroviral-Naive Patients
Jointly Sponsored by:
|
|
|
 |
About the Program
- Program Overview
- Program Objectives
- Commercial Support Acknowledgement
- Target Audience
- Course Directors
- Faculty
- Enduring Web Program
- Accreditation Statement
- Credit Designation Statement
- Disclosure of Conflicts of Interest
- Disclosure of Unlabeled Use
- Instructions for Participation and Credit
- Disclaimer
Program Overview
The construction of an ARV treatment regimen that maximizes the patient's chance for successful ARV therapy and minimizes the short- and long-term risk of morbidity and mortality is complex. Clinicians caring for HIV-positive patients need to understand the importance of selecting - and have the ability and knowledge to select - an ARV regimen that maximizes the patient's chance for virologic success and a long, healthy life. This requires that the clinician have (1) a familiarity with the clinical research assessing ART in ART-naïve patients, (2) an understanding of the complex factors involved in ARV selection, and (3) an ability to assess the needs and abilities of the individual patient so care can be individualized.
This highly interactive, case-based program will provide clinicians of varying knowledge and skill levels with the requisite knowledge and clinical skills they need to choose the best regimen for each patient and is designed to address educational gaps that limit effective ARV therapy from being provided to HIV-positive patients.
Back to Top
Program Objectives
Upon completion of the program, participants will demonstrate the ability to:
-
Discuss key clinical research evaluating ART regimens and strategies in ART-naïve patients;
-
Use data regarding ARV tolerance, adverse events, resistance barriers, pharmacokinetics, and other issues to improve initial ART success rates;
-
Explain the role individual patient characteristics or desires may play in selecting initial ART;
-
Select ART regimens that maximize each patient's chance of long-term success.
Release Date: October 19, 2010
Expiration Date: October 18, 2011
Estimated time to complete the activity: 2 hours
Media: Internet
Commercial Support Acknowledgement
This activity is supported by an unrestricted educational grant from Merck & Co., Inc.
Back to Top
Target Audience
This activity is intended for physicians, physicians' assistants, advanced practice nurses, and other health care professionals actively involved in the treatment and management of patients with HIV-infection. It is tuition-free and there are no prerequisites.
Back to Top
Course Directors
|
Calvin J. Cohen, MD, MS |
Joseph Eron, MD Professor, University of North Carolina School of Medicine Chapel Hill, North Carolina |
Back to Top
Faculty
| Edwin DeJesus, MD Medical Director, Orlando Immunology Center Orlando, Florida |
Trevor Hawkins, MD Associate Professor, University of New Mexico Medical Director, Southwest CARE Center Santa Fe, New Mexico |
|
Richard A. Elion , MD Associate Professor of Clinical Medicine, George Washington University Medical Center Washington, DC |
Ian Frank, MD Professor of Medicine, Director, Antiretroviral Clinical Research University of Pennsylvania Philadelphia, Pennsylvania |
|
David Wohl, MD Associate Professor of Medicine, Division of Infectious Diseases, School of Medicine, The University of North Carolina, Chapel Hill Co-Director of HIV Services for the North Carolina Department of Corrections Chapel Hill, North Carolina |
Back to Top
Enduring Web Program
| |
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Back to Top
Credit Designation Statement
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations.PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Calvin Cohen, MD:
- Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; ViiV
- Consulting Fees: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; Abbott
- Speakers Bureau: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec
Edwin DeJesus, MD
- Contracted Research: Abbott; Achillion; Avexa; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Hoffman LaRoche; Merck; Pfizer; Schering Plough; Taimed; Tobira; Tibotec; Vertex
- Consulting Fees: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec; Vertex
- Speakers Bureau: Gilead Sciences; Tibotec; Virco
Richard Elion, MD
- Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; GlaxoSmithKline; Rapid
- Consulting Fees: Gilead; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec
- Speakers Bureau: Gilead; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec
Joseph Eron, MD:
- Contracted Research: Merck, GlaxoSmithKline, TaiMed
- Consulting Fees: Merck, Avexa, BMS, GSK, Tibotec, Virco Laboratories, Pfizer, Tobira, Chimerix, Myriad, Inhibitex
- Speakers' Bureau/Honorarium: Roche, BMS, Virco Laboratories
Ian Frank, MD:
- Contracted Research: GlaxoSmithKline, Merck & Co.
- Consulting Fees: Gilead; Tibotec, Bristol-Meyers Squibb
- Speakers Bureau: Gilead; Tibotec
Trevor Hawkins, MD
- Contracted Research: Gilead; GlaxoSmithKline
- Consulting Fees: Gilead; Tibotec
- Speakers Bureau: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec
David Wohl, MD
- Consulting Fees: Abbott, Tibotec, Gilead
- Contracted Research: Merck, GSK, Tibotec, Gilead
- Fees for non-CME/CE Services: Gilead, Abbott, Tibotec, Bristol-Meyers Squibb, Merck
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ViralEd, LLC, and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, LLC, and Merck. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Back to Top
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period, October 19, 2010 through October 18, 2011 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
You may complete the Post-test on-line at http://www.cmeuniversity.com/.
-
Click on "Find Post-Test/Evaluation by Course" on the navigation menu
-
Search by project ID 7025
- Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.
| |
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Back to Top
Share this page:
